{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T01:25:44Z","timestamp":1784942744269,"version":"3.55.0"},"reference-count":149,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008599","name":"Alzheimerfonden","doi-asserted-by":"publisher","award":["K8020071398"],"award-info":[{"award-number":["K8020071398"]}],"id":[{"id":"10.13039\/501100008599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008599","name":"Alzheimerfonden","doi-asserted-by":"publisher","award":["AF-980746"],"award-info":[{"award-number":["AF-980746"]}],"id":[{"id":"10.13039\/501100008599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008599","name":"Alzheimerfonden","doi-asserted-by":"publisher","award":["2022-01324"],"award-info":[{"award-number":["2022-01324"]}],"id":[{"id":"10.13039\/501100008599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008599","name":"Alzheimerfonden","doi-asserted-by":"publisher","award":["2017-0243"],"award-info":[{"award-number":["2017-0243"]}],"id":[{"id":"10.13039\/501100008599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008599","name":"Alzheimerfonden","doi-asserted-by":"publisher","award":["-939721"],"award-info":[{"award-number":["-939721"]}],"id":[{"id":"10.13039\/501100008599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008599","name":"Alzheimerfonden","doi-asserted-by":"publisher","award":["2022-0006"],"award-info":[{"award-number":["2022-0006"]}],"id":[{"id":"10.13039\/501100008599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008599","name":"Alzheimerfonden","doi-asserted-by":"publisher","award":["-968270"],"award-info":[{"award-number":["-968270"]}],"id":[{"id":"10.13039\/501100008599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008599","name":"Alzheimerfonden","doi-asserted-by":"publisher","award":["-930351"],"award-info":[{"award-number":["-930351"]}],"id":[{"id":"10.13039\/501100008599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013278","name":"EU Joint Programme \u2013 Neurodegenerative Disease Research","doi-asserted-by":"publisher","award":["JPND2021-00694"],"award-info":[{"award-number":["JPND2021-00694"]}],"id":[{"id":"10.13039\/100013278","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017510","name":"UK Dementia Research Institute","doi-asserted-by":"publisher","award":["UKDRI-1003"],"award-info":[{"award-number":["UKDRI-1003"]}],"id":[{"id":"10.13039\/501100017510","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021720","name":"Olav Thon Stiftelsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021720","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007625","name":"Cure Alzheimer's Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007436","name":"Familjen Erling-Perssons Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007678","name":"Center for Modelling and Simulation in the Biosciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007678","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","award":["201809-2016862"],"award-info":[{"award-number":["201809-2016862"]}],"id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2017-00915"],"award-info":[{"award-number":["2017-00915"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2022-00732"],"award-info":[{"award-number":["2022-00732"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["2022-01018"],"award-info":[{"award-number":["2022-01018"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["ZEN-21-848495"],"award-info":[{"award-number":["ZEN-21-848495"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["SG-23-1038904 QC"],"award-info":[{"award-number":["SG-23-1038904 QC"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["-21-831381-C"],"award-info":[{"award-number":["-21-831381-C"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["-21-831376-C"],"award-info":[{"award-number":["-21-831376-C"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["-21-831377-C"],"award-info":[{"award-number":["-21-831377-C"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009673","name":"Gun och Bertil Stohnes Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009673","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["860197"],"award-info":[{"award-number":["860197"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mcponline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular & Cellular Proteomics"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.mcpro.2024.100721","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T20:54:45Z","timestamp":1705697685000},"page":"100721","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Alzheimer's Disease Biomarker Analysis Using Targeted Mass Spectrometry"],"prefix":"10.1016","volume":"23","author":[{"given":"Johan","family":"Gobom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Brinkmalm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6958-2393","authenticated-orcid":false,"given":"Gunnar","family":"Brinkmalm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3930-4354","authenticated-orcid":false,"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcpro.2024.100721_bib1","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/ca.980080612","article-title":"An English translation of Alzheimer's 1907 paper, \u201cUber eine eigenartige Erkankung der Hirnrinde\u201d","volume":"8","author":"Alzheimer","year":"1995","journal-title":"Clin. Anat."},{"key":"10.1016\/j.mcpro.2024.100721_bib2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer's disease: the amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.mcpro.2024.100721_bib3","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","article-title":"Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study","volume":"14","author":"McDade","year":"2022","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.mcpro.2024.100721_bib4","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer\u2019s disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.mcpro.2024.100721_bib5","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A\u00a0randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Abeta protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.mcpro.2024.100721_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"Van Dyck","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.mcpro.2024.100721_bib7","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1073\/pnas.83.13.4913","article-title":"Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology","volume":"83","author":"Grundke-Iqbal","year":"1986","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mcpro.2024.100721_bib8","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1093\/brain\/awy146","article-title":"Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated","volume":"141","author":"Robinson","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.mcpro.2024.100721_bib9","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1002\/pmic.201500449","article-title":"Advances in targeted proteomics and applications to biomedical research","volume":"16","author":"Shi","year":"2016","journal-title":"Proteomics"},{"key":"10.1016\/j.mcpro.2024.100721_bib10","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/pmic.201500543","article-title":"Parallel reaction monitoring using quadrupole-Orbitrap mass spectrometer: principle and applications","volume":"16","author":"Bourmaud","year":"2016","journal-title":"Proteomics"},{"key":"10.1016\/j.mcpro.2024.100721_bib11","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1002\/mas.21781","article-title":"Advances in data-independent acquisition mass spectrometry towards comprehensive digital proteome landscape","volume":"42","author":"Kitata","year":"2023","journal-title":"Mass Spectrom. Rev."},{"key":"10.1016\/j.mcpro.2024.100721_bib12","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1021\/acs.jproteome.3c00357","article-title":"Evaluating the performance of the astral mass analyzer for quantitative proteomics using data-independent acquisition","volume":"22","author":"Heil","year":"2023","journal-title":"J.\u00a0Proteome Res."},{"key":"10.1016\/j.mcpro.2024.100721_bib13","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/s41592-020-00998-0","article-title":"diaPASEF: parallel accumulation\u2013serial fragmentation combined with data-independent acquisition","volume":"17","author":"Meier","year":"2020","journal-title":"Nat. Methods"},{"key":"10.1016\/j.mcpro.2024.100721_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2022.100279","article-title":"Rapid and in-depth coverage of the (Phospho-)Proteome with deep libraries and optimal window design for dia-PASEF","volume":"21","author":"Skowronek","year":"2022","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.mcpro.2024.100721_bib15","doi-asserted-by":"crossref","first-page":"66","DOI":"10.5770\/cgj.19.207","article-title":"The new criteria for Alzheimer\u2019s disease - implications for geriatricians\u2217","volume":"19","author":"Molin","year":"2016","journal-title":"Can. Geriatr. J."},{"key":"10.1016\/j.mcpro.2024.100721_bib16","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","article-title":"CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis","volume":"15","author":"Olsson","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.mcpro.2024.100721_bib17","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13195-015-0114-5","article-title":"Cerebrospinal fluid amyloid-\u03b2 42\/40 ratio in clinical setting of memory centers: a multicentric study","volume":"7","author":"Dumurgier","year":"2015","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.mcpro.2024.100721_bib18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13195-019-0485-0","article-title":"Advantages and disadvantages of the use of the CSF Amyloid \u03b2 (A\u03b2) 42\/40 ratio in the diagnosis of Alzheimer\u2019s disease","volume":"11","author":"Hansson","year":"2019","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.mcpro.2024.100721_bib19","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1471-4159.2006.04404.x","article-title":"Amyloid beta peptide ratio 42\/40 but not Abeta 42 correlates with phospho-tau in patients with low- and high-CSF Abeta 40 load","volume":"101","author":"Wiltfang","year":"2007","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.mcpro.2024.100721_bib20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1515\/cclm-2021-0651","article-title":"Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid","volume":"60","author":"Gobom","year":"2022","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.mcpro.2024.100721_bib21","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1021\/pr050475v","article-title":"Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry","volume":"5","author":"Portelius","year":"2006","journal-title":"J.\u00a0Proteome Res."},{"key":"10.1016\/j.mcpro.2024.100721_bib22","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.neulet.2006.09.044","article-title":"An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid","volume":"409","author":"Portelius","year":"2006","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.mcpro.2024.100721_bib23","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1021\/pr0703627","article-title":"Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry","volume":"6","author":"Portelius","year":"2007","journal-title":"J.\u00a0Proteome Res."},{"key":"10.1016\/j.mcpro.2024.100721_bib24","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3233\/JAD-2012-120508","article-title":"Amyloid-beta(1-15\/16) as a marker for gamma-secretase inhibition in Alzheimer's disease","volume":"31","author":"Portelius","year":"2012","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.mcpro.2024.100721_bib25","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3892\/mmr.2012.774","article-title":"The amyloid-beta isoform pattern in cerebrospinal fluid in familial PSEN1 M139T- and L286P-associated Alzheimer's disease","volume":"5","author":"Portelius","year":"2012","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.mcpro.2024.100721_bib26","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.2174\/13816128113199990499","article-title":"Characterization of the effect of a novel gamma-secretase modulator on Abeta: a clinically translatable model","volume":"20","author":"Portelius","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.mcpro.2024.100721_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0031084","article-title":"BACE1 inhibition induces a specific cerebrospinal fluid beta-amyloid pattern that identifies drug effects in the central nervous system","volume":"7","author":"Mattsson","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.mcpro.2024.100721_bib28","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ab.2011.08.010","article-title":"Quantitation of amyloid beta peptides Abeta(1-38), Abeta(1-40), and Abeta(1-42) in human cerebrospinal fluid by ultra-performance liquid chromatography-tandem mass spectrometry","volume":"419","author":"Lame","year":"2011","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.mcpro.2024.100721_bib29","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1373\/clinchem.2013.220392","article-title":"Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid-beta in cerebrospinal fluid","volume":"60","author":"Leinenbach","year":"2014","journal-title":"Clin. Chem."},{"key":"10.1016\/j.mcpro.2024.100721_bib30","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3233\/JAD-132489","article-title":"Qualification of a surrogate matrix-based absolute quantification method for amyloid-beta(4)(2) in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry","volume":"41","author":"Korecka","year":"2014","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.mcpro.2024.100721_bib31","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/jnc.13838","article-title":"Reference measurement procedure for CSF amyloid beta (Abeta)1-42 and the CSF Abeta1-42\/Abeta1-40 ratio - a cross-validation study against amyloid PET","volume":"139","author":"Pannee","year":"2016","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.mcpro.2024.100721_bib32","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/alz.12145","article-title":"First amyloid \u03b21-42 certified reference material for re-calibrating commercial immunoassays","volume":"16","author":"Boulo","year":"2020","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.mcpro.2024.100721_bib33","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ab.2013.04.031","article-title":"Amyloid-beta isoform metabolism quantitation by stable isotope-labeled kinetics","volume":"440","author":"Mawuenyega","year":"2013","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.mcpro.2024.100721_bib34","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1038\/s41598-019-41897-5","article-title":"Synthetic standard aided quantification and structural characterization of amyloid-beta glycopeptides enriched from cerebrospinal fluid of Alzheimer's disease patients","volume":"9","author":"Nilsson","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.mcpro.2024.100721_bib35","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1021\/acs.jproteome.1c00424","article-title":"Multiplex mass spectrometry analysis of amyloid proteins in human plasma for Alzheimer's disease diagnosis","volume":"20","author":"Ni","year":"2021","journal-title":"J.\u00a0Proteome Res."},{"key":"10.1016\/j.mcpro.2024.100721_bib36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.neulet.2014.04.041","article-title":"The amyloid-beta degradation pattern in plasma--a possible tool for clinical trials in Alzheimer's disease","volume":"573","author":"Pannee","year":"2014","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.mcpro.2024.100721_bib37","doi-asserted-by":"crossref","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","article-title":"High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis","volume":"93","author":"Schindler","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.mcpro.2024.100721_bib38","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-beta biomarkers for Alzheimer's disease","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.mcpro.2024.100721_bib39","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.bbadis.2004.09.008","article-title":"Tau pathology in Alzheimer disease and other tauopathies","volume":"1739","author":"Iqbal","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.mcpro.2024.100721_bib40","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/j.1460-2075.1989.tb03390.x","article-title":"Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain","volume":"8","author":"Goedert","year":"1989","journal-title":"EMBO J."},{"key":"10.1016\/j.mcpro.2024.100721_bib41","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1001\/archneur.58.3.373","article-title":"Evaluation of CSF-tau and CSF-A\u03b242 as diagnostic markers for Alzheimer disease in clinical practice","volume":"58","author":"Andreasen","year":"2001","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.mcpro.2024.100721_bib42","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jalz.2014.02.004","article-title":"Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease","volume":"11","author":"Blennow","year":"2015","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.mcpro.2024.100721_bib43","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","article-title":"Cerebrospinal fluid and plasma biomarkers in Alzheimer disease","volume":"6","author":"Blennow","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.mcpro.2024.100721_bib44","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/BF02815140","article-title":"Tau protein in cerebrospinal fluid","volume":"26","author":"Blennow","year":"1995","journal-title":"Mol. Chem. Neuropathol."},{"key":"10.1016\/j.mcpro.2024.100721_bib45","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1093\/clinchem\/47.10.1776","article-title":"Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values","volume":"47","author":"Sjogren","year":"2001","journal-title":"Clin. Chem."},{"key":"10.1016\/j.mcpro.2024.100721_bib46","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1602\/neurorx.1.2.213","article-title":"Cerebrospinal fluid protein biomarkers for Alzheimer\u2019s disease","volume":"1","author":"Blennow","year":"2004","journal-title":"NeuroRX"},{"key":"10.1016\/j.mcpro.2024.100721_bib47","series-title":"Cerebrospinal Fluid and Plasma Tau as a Biomarker for Brain Tauopathy","first-page":"393","author":"Shoji","year":"2019"},{"key":"10.1016\/j.mcpro.2024.100721_bib48","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1001\/jamaneurol.2013.6455","article-title":"Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish Mortality Registry","volume":"71","author":"Skillback","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.mcpro.2024.100721_bib49","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0304-3940(00)01697-9","article-title":"Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke","volume":"297","author":"Hesse","year":"2001","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.mcpro.2024.100721_bib50","doi-asserted-by":"crossref","DOI":"10.2217\/cnc-2022-0004","article-title":"Tau as a fluid biomarker of concussion and neurodegeneration","volume":"7","author":"Hossain","year":"2022","journal-title":"Concussion"},{"key":"10.1016\/j.mcpro.2024.100721_bib51","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1001\/archneur.59.8.1267","article-title":"Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231","volume":"59","author":"Buerger","year":"2002","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.mcpro.2024.100721_bib52","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archpsyc.61.1.95","article-title":"Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study","volume":"61","author":"Hampel","year":"2004","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.mcpro.2024.100721_bib53","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S0002-9440(10)62554-0","article-title":"Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients: an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay","volume":"160","author":"Hu","year":"2002","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.mcpro.2024.100721_bib54","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0304-3940(99)00476-0","article-title":"Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease","volume":"270","author":"Ishiguro","year":"1999","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.mcpro.2024.100721_bib55","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0304-3940(00)01178-2","article-title":"Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients","volume":"287","author":"Kohnken","year":"2000","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.mcpro.2024.100721_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076523","article-title":"Characterization of novel CSF Tau and ptau biomarkers for Alzheimer's disease","volume":"8","author":"Meredith","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.mcpro.2024.100721_bib57","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1007\/s00216-009-3208-8","article-title":"Immuno-PCR-based quantification of multiple phosphorylated tau-epitopes linked to Alzheimer's disease","volume":"395","author":"Singer","year":"2009","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.mcpro.2024.100721_bib58","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1038\/s41467-020-15436-0","article-title":"Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease","volume":"11","author":"Janelidze","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mcpro.2024.100721_bib59","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/alz.12236","article-title":"Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis","volume":"17","author":"Karikari","year":"2021","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.mcpro.2024.100721_bib60","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202012921","article-title":"Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in Abeta pathology are detected","volume":"12","author":"Suarez-Calvet","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.mcpro.2024.100721_bib61","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1046\/j.1471-4159.1998.71062465.x","article-title":"New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry","volume":"71","author":"Hanger","year":"1998","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.mcpro.2024.100721_bib62","doi-asserted-by":"crossref","first-page":"23645","DOI":"10.1074\/jbc.M703269200","article-title":"Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis","volume":"282","author":"Hanger","year":"2007","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.mcpro.2024.100721_bib63","doi-asserted-by":"crossref","first-page":"17047","DOI":"10.1016\/S0021-9258(18)41890-X","article-title":"Protein sequence and mass spectrometric analyses of tau in the Alzheimer's disease brain","volume":"267","author":"Hasegawa","year":"1992","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.mcpro.2024.100721_bib64","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1373\/clinchem.2013.216515","article-title":"Quantification of tau in cerebrospinal fluid by immunoaffinity enrichment and tandem mass spectrometry","volume":"60","author":"McAvoy","year":"2014","journal-title":"Clin. Chem."},{"key":"10.1016\/j.mcpro.2024.100721_bib65","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1021\/pr7008669","article-title":"Characterization of tau in cerebrospinal fluid using mass spectrometry","volume":"7","author":"Portelius","year":"2008","journal-title":"J.\u00a0Proteome Res."},{"key":"10.1016\/j.mcpro.2024.100721_bib66","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00401-018-1948-2","article-title":"Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer's disease","volume":"137","author":"Cicognola","year":"2019","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.mcpro.2024.100721_bib67","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3389\/fnagi.2019.00121","article-title":"Tau phosphorylation rates measured by mass spectrometry differ in the intracellular brain vs. extracellular cerebrospinal fluid compartments and are differentially affected by Alzheimer's disease","volume":"11","author":"Barthelemy","year":"2019","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.mcpro.2024.100721_bib68","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41591-020-0781-z","article-title":"A\u00a0soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease","volume":"26","author":"Barthelemy","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.mcpro.2024.100721_bib69","doi-asserted-by":"crossref","first-page":"12241","DOI":"10.1016\/S0021-9258(20)71345-1","article-title":"The purification of tau protein and the occurrence of two phosphorylation states of tau in brain","volume":"259","author":"Lindwall","year":"1984","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.mcpro.2024.100721_bib70","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3389\/fnins.2015.00302","article-title":"Antibody-free quantification of seven tau peptides in human CSF using targeted mass spectrometry","volume":"9","author":"Bros","year":"2015","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.mcpro.2024.100721_bib71","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1021\/acs.jproteome.5b01001","article-title":"Tau protein quantification in human cerebrospinal fluid by targeted mass spectrometry at high sequence coverage provides insights into its primary structure heterogeneity","volume":"15","author":"Barthelemy","year":"2016","journal-title":"J.\u00a0Proteome Res."},{"key":"10.1016\/j.mcpro.2024.100721_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0269157","article-title":"An immuno-enrichment free, validated quantification of tau protein in human CSF by LC-MS\/MS","volume":"17","author":"Self","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.mcpro.2024.100721_bib73","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13024-022-00586-0","article-title":"Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer's disease continuum","volume":"17","author":"Gobom","year":"2022","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.mcpro.2024.100721_bib74","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1212\/WNL.56.1.127","article-title":"Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease","volume":"56","author":"Masliah","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.mcpro.2024.100721_bib75","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/ana.410300410","article-title":"Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment","volume":"30","author":"Terry","year":"1991","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.mcpro.2024.100721_bib76","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3233\/JAD-2005-7203","article-title":"Differential loss of synaptic proteins in Alzheimer's disease: implications for synaptic dysfunction","volume":"7","author":"Reddy","year":"2005","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.mcpro.2024.100721_bib77","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.jalz.2014.10.009","article-title":"Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease","volume":"11","author":"Kvartsberg","year":"2015","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.mcpro.2024.100721_bib78","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1093\/brain\/awv267","article-title":"Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer\u2019s disease","volume":"138","author":"Portelius","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.mcpro.2024.100721_bib79","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.jalz.2018.01.012","article-title":"Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer's disease","volume":"14","author":"Sutphen","year":"2018","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.mcpro.2024.100721_bib80","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/jamaneurol.2016.0086","article-title":"Diagnostic and prognostic utility of the synaptic marker neurogranin in Alzheimer disease","volume":"73","author":"Tarawneh","year":"2016","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.mcpro.2024.100721_bib81","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13024-018-0279-z","article-title":"Alzheimer-associated cerebrospinal fluid fragments of neurogranin are generated by Calpain-1 and prolyl endopeptidase","volume":"13","author":"Becker","year":"2018","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.mcpro.2024.100721_bib82","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/jnc.15252","article-title":"Molecular forms of neurogranin in cerebrospinal fluid","volume":"157","author":"Nazir","year":"2021","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.mcpro.2024.100721_bib83","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13195-015-0124-3","article-title":"Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer\u2019s disease patients and healthy controls","volume":"7","author":"Kvartsberg","year":"2015","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.mcpro.2024.100721_bib84","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s13195-020-00748-6","article-title":"Full-length and C-terminal neurogranin in Alzheimer\u2019s disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays","volume":"12","author":"\u00d6hrfelt","year":"2020","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.mcpro.2024.100721_bib85","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00401-018-1932-x","article-title":"Current state of Alzheimer\u2019s fluid biomarkers","volume":"136","author":"Molinuevo","year":"2018","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.mcpro.2024.100721_bib86","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1136\/jnnp-2018-320155","article-title":"CSF neurogranin as a neuronal damage marker in CJD: a comparative study with AD","volume":"90","author":"Blennow","year":"2019","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.mcpro.2024.100721_bib87","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1212\/WNL.0000000000002423","article-title":"Increased CSF neurogranin concentration is specific to Alzheimer disease","volume":"86","author":"Wellington","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.mcpro.2024.100721_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2021.101491","article-title":"The prognostic utility of CSF neurogranin in predicting future cognitive decline in the Alzheimer's disease continuum: a systematic review and meta-analysis with narrative synthesis","volume":"72","author":"Yoong","year":"2021","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.mcpro.2024.100721_bib89","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.jalz.2015.05.012","article-title":"C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease","volume":"11","author":"De Vos","year":"2015","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.mcpro.2024.100721_bib90","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1750-1326-9-53","article-title":"SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer\u2019s disease","volume":"9","author":"Brinkmalm","year":"2014","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.mcpro.2024.100721_bib91","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1074\/mcp.M114.040113","article-title":"Targeting synaptic pathology with a novel affinity mass spectrometry approach","volume":"13","author":"Brinkmalm","year":"2014","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.mcpro.2024.100721_bib92","doi-asserted-by":"crossref","first-page":"15781","DOI":"10.1073\/pnas.95.26.15781","article-title":"Conserved structural features of the synaptic fusion complex: SNARE proteins reclassified as Q- and R-SNAREs","volume":"95","author":"Fasshauer","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mcpro.2024.100721_bib93","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/26412","article-title":"Crystal structure of a SNARE complex involved in synaptic exocytosis at 2.4 A resolution","volume":"395","author":"Sutton","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.mcpro.2024.100721_bib94","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.neuron.2013.10.026","article-title":"Synaptotagmin-1 and synaptotagmin-7 trigger synchronous and asynchronous phases of neurotransmitter release","volume":"80","author":"Bacaj","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.mcpro.2024.100721_bib95","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.1002\/1873-3468.13193","article-title":"Models of synaptotagmin-1 to trigger Ca(2+)-dependent vesicle fusion","volume":"592","author":"Park","year":"2018","journal-title":"FEBS Lett."},{"key":"10.1016\/j.mcpro.2024.100721_bib96","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/BF02815094","article-title":"Synaptotagmin, a synaptic vesicle protein, is present in human cerebrospinal fluid","volume":"27","author":"Davidsson","year":"1996","journal-title":"Mol. Chem. Neuropathol."},{"key":"10.1016\/j.mcpro.2024.100721_bib97","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13195-016-0208-8","article-title":"The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease","volume":"8","author":"\u00d6hrfelt","year":"2016","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.mcpro.2024.100721_bib98","doi-asserted-by":"crossref","first-page":"e953","DOI":"10.1212\/WNL.0000000000010131","article-title":"Dissection of synaptic pathways through the CSF biomarkers for predicting Alzheimer disease","volume":"95","author":"Tible","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.mcpro.2024.100721_bib99","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.3390\/biomedicines10123241","article-title":"Synucleins: new data on misfolding, aggregation and role in diseases","volume":"10","author":"Surguchov","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.mcpro.2024.100721_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2019.134316","article-title":"\u03b1-Synuclein pathology in Parkinson's disease and related \u03b1-synucleinopathies","volume":"709","author":"Henderson","year":"2019","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.mcpro.2024.100721_bib101","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/mds.28941","article-title":"Alpha and beta synucleins: from pathophysiology to clinical application as biomarkers","volume":"37","author":"Barba","year":"2022","journal-title":"Mov Disord."},{"key":"10.1016\/j.mcpro.2024.100721_bib102","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1074\/mcp.M116.059915","article-title":"Alpha-, beta-, and gamma-synuclein quantification in cerebrospinal fluid by multiple reaction monitoring reveals increased concentrations in Alzheimer's and Creutzfeldt-Jakob disease but No alteration in synucleinopathies","volume":"15","author":"Oeckl","year":"2016","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.mcpro.2024.100721_bib103","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13195-022-01125-1","article-title":"\u03b2-Synuclein as a candidate blood biomarker for synaptic degeneration in Alzheimer\u2019s disease","volume":"14","author":"Mohaupt","year":"2022","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.mcpro.2024.100721_bib104","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3389\/fnana.2018.00040","article-title":"Shaping synapses by the neural extracellular matrix","volume":"12","author":"Ferrer-Ferrer","year":"2018","journal-title":"Front. Neuroanat."},{"key":"10.1016\/j.mcpro.2024.100721_bib105","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00702-021-02411-2","article-title":"Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration","volume":"129","author":"G\u00f3mez De San Jos\u00e9","year":"2022","journal-title":"J.\u00a0Neural Transm."},{"key":"10.1016\/j.mcpro.2024.100721_bib106","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/mds.29287","article-title":"Cerebrospinal fluid biomarkers of synaptic dysfunction are altered in Parkinson's disease and related disorders","volume":"38","author":"Nilsson","year":"2023","journal-title":"Mov. Disord."},{"key":"10.1016\/j.mcpro.2024.100721_bib107","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1046\/j.1471-4159.1994.63062259.x","article-title":"Subcellular localisation of 14-3-3 isoforms in rat brain using specific antibodies","volume":"63","author":"Martin","year":"1994","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.mcpro.2024.100721_bib108","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8407609","article-title":"14-3-3 proteins in glutamatergic synapses","volume":"2018","author":"Zhang","year":"2018","journal-title":"Neural Plast."},{"key":"10.1016\/j.mcpro.2024.100721_bib109","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0896-6273(00)80948-4","article-title":"Leonardo, a Drosophila 14-3-3 protein involved in learning, regulates presynaptic function","volume":"19","author":"Broadie","year":"1997","journal-title":"Neuron"},{"key":"10.1016\/j.mcpro.2024.100721_bib110","first-page":"152","article-title":"14-3-3 proteins in neurological disorders","volume":"3","author":"Foote","year":"2012","journal-title":"Int. J. Biochem. Mol. Biol."},{"key":"10.1016\/j.mcpro.2024.100721_bib111","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13195-019-0564-2","article-title":"CSF synaptic protein concentrations are raised in those with atypical Alzheimer's disease but not frontotemporal dementia","volume":"11","author":"Clarke","year":"2019","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.mcpro.2024.100721_bib112","doi-asserted-by":"crossref","DOI":"10.1002\/prca.201800105","article-title":"Quantitative proteomic profiling of cerebrospinal fluid to identify candidate biomarkers for Alzheimer's disease","volume":"13","author":"Sathe","year":"2019","journal-title":"Proteomics Clin. Appl."},{"key":"10.1016\/j.mcpro.2024.100721_bib113","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00216-016-9900-6","article-title":"Extracellular matrix proteomics in schizophrenia and Alzheimer\u2019s disease","volume":"409","author":"Sethi","year":"2017","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.mcpro.2024.100721_bib114","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcab261","article-title":"VGF as a biomarker and therapeutic target in neurodegenerative and psychiatric diseases","volume":"3","author":"Quinn","year":"2021","journal-title":"Brain Commun."},{"key":"10.1016\/j.mcpro.2024.100721_bib115","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1471-2377-11-101","article-title":"Identification of a novel biomarker candidate, a 4.8-kDa peptide fragment from a neurosecretory protein VGF precursor, by proteomic analysis of cerebrospinal fluid from children with acute encephalopathy using SELDI-TOF-MS","volume":"11","author":"Asano","year":"2011","journal-title":"BMC Neurol."},{"key":"10.1016\/j.mcpro.2024.100721_bib116","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.neuroscience.2010.06.057","article-title":"Granins as disease-biomarkers: translational potential for psychiatric and neurological disorders","volume":"170","author":"Bartolomucci","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.mcpro.2024.100721_bib117","first-page":"683","article-title":"Distribution of VGF peptides in the human cortex and their selective changes in Parkinson's and Alzheimer's diseases","volume":"217","author":"Cocco","year":"2010","journal-title":"J.\u00a0Anat."},{"key":"10.1016\/j.mcpro.2024.100721_bib118","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1021\/pr501076j","article-title":"An integrated workflow for multiplex CSF proteomics and peptidomics-identification of candidate cerebrospinal fluid biomarkers of Alzheimer's disease","volume":"14","author":"Holtta","year":"2015","journal-title":"J.\u00a0Proteome Res."},{"key":"10.1016\/j.mcpro.2024.100721_bib119","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.expneurol.2005.08.002","article-title":"Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF","volume":"196","author":"Ruetschi","year":"2005","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.mcpro.2024.100721_bib120","doi-asserted-by":"crossref","first-page":"92","DOI":"10.7150\/ijms.5.92","article-title":"Vgf is a novel biomarker associated with muscle weakness in amyotrophic lateral sclerosis (ALS), with a potential role in disease pathogenesis","volume":"5","author":"Zhao","year":"2008","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.mcpro.2024.100721_bib121","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ymeth.2012.03.018","article-title":"A\u00a0novel peptidomics approach to detect markers of Alzheimer's disease in cerebrospinal fluid","volume":"56","author":"Wijte","year":"2012","journal-title":"Methods"},{"key":"10.1016\/j.mcpro.2024.100721_bib122","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41583-020-00415-7","article-title":"Neurexins: molecular codes for shaping neuronal synapses","volume":"22","author":"Gomez","year":"2021","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.mcpro.2024.100721_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103793","article-title":"Quantification of the trans-synaptic partners neurexin-neuroligin in CSF of neurodegenerative diseases by parallel reaction monitoring mass spectrometry","volume":"75","author":"Camporesi","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.mcpro.2024.100721_bib124","article-title":"Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease","volume":"13","author":"Nilsson","year":"2021","journal-title":"Alzheimers Dement. (Amst.)"},{"key":"10.1016\/j.mcpro.2024.100721_bib125","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1001\/jama.1997.03550160069041","article-title":"Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis","volume":"278","author":"Farrer","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.mcpro.2024.100721_bib126","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.3390\/nu14122474","article-title":"Simultaneous mass spectrometry-based apolipoprotein profiling and apolipoprotein E phenotyping in patients with ASCVD and mild cognitive impairment","volume":"14","author":"Begcevic Brkovic","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.mcpro.2024.100721_bib127","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00401-014-1266-2","article-title":"Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer\u2019s disease patients and controls","volume":"127","author":"Mart\u00ednez-Morillo","year":"2014","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.mcpro.2024.100721_bib128","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1074\/mcp.M112.018861","article-title":"Total ApoE and ApoE4 isoform assays in an Alzheimer's disease case-control study by targeted mass spectrometry (n=669): a pilot assay for methionine-containing proteotypic peptides","volume":"11","author":"Simon","year":"2012","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.mcpro.2024.100721_bib129","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13195-020-00585-7","article-title":"Quantification of total apolipoprotein E and its isoforms in cerebrospinal fluid from patients with neurodegenerative diseases","volume":"12","author":"Minta","year":"2020","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.mcpro.2024.100721_bib130","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1093\/brain\/awaa098","article-title":"Neurofilaments: neurobiological foundations for biomarker applications","volume":"143","author":"Gafson","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.mcpro.2024.100721_bib131","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcac045","article-title":"A\u00a0map of neurofilament light chain species in brain and cerebrospinal fluid and alterations in Alzheimer\u2019s disease","volume":"4","author":"Budelier","year":"2022","journal-title":"Brain Commun."},{"key":"10.1016\/j.mcpro.2024.100721_bib132","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.nbd.2017.04.007","article-title":"NF-L in cerebrospinal fluid and serum is a biomarker of neuronal damage in an inducible mouse model of neurodegeneration","volume":"104","author":"Brureau","year":"2017","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.mcpro.2024.100721_bib133","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2022-000395","article-title":"Neurofilament light oligomers in neurodegenerative diseases: quantification by homogeneous immunoassay in cerebrospinal fluid","volume":"5","author":"Meda","year":"2023","journal-title":"BMJ Neurol. Open"},{"key":"10.1016\/j.mcpro.2024.100721_bib134","series-title":"Endosomal-Lysosomal Dysfunction in Metabolic Diseases and Alzheimer\u2019s Disease","first-page":"303","author":"Almeida","year":"2020"},{"key":"10.1016\/j.mcpro.2024.100721_bib135","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12014-016-9104-2","article-title":"Targeting LAMP2 in human cerebrospinal fluid with a combination of immunopurification and high resolution parallel reaction monitoring mass spectrometry","volume":"13","author":"Sj\u00f6din","year":"2016","journal-title":"Clin. Proteomics"},{"key":"10.1016\/j.mcpro.2024.100721_bib136","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13195-019-0533-9","article-title":"Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer\u2019s and Parkinson\u2019s disease","volume":"11","author":"Sj\u00f6din","year":"2019","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.mcpro.2024.100721_bib137","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13024-018-0298-9","article-title":"New insights into the role of TREM2 in Alzheimer\u2019s disease","volume":"13","author":"Gratuze","year":"2018","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.mcpro.2024.100721_bib138","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13024-016-0071-x","article-title":"Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer\u2019s disease","volume":"11","author":"Heslegrave","year":"2016","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.mcpro.2024.100721_bib139","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3233\/JAD-2010-1221","article-title":"Alzheimer's disease and the amyloid-\u03b2 peptide","volume":"19","author":"Murphy","year":"2010","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.mcpro.2024.100721_bib140","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1021\/pr5006058","article-title":"Intact protein analysis of ubiquitin in cerebrospinal fluid by multiple reaction monitoring reveals differences in Alzheimer\u2019s disease and frontotemporal lobar degeneration","volume":"13","author":"Oeckl","year":"2014","journal-title":"J.\u00a0Proteome Res."},{"key":"10.1016\/j.mcpro.2024.100721_bib141","doi-asserted-by":"crossref","DOI":"10.1002\/prca.201700100","article-title":"Mass spectrometric analysis of cerebrospinal fluid ubiquitin in Alzheimer's disease and parkinsonian disorders","volume":"11","author":"Sj\u00f6din","year":"2017","journal-title":"Proteomics Clin. Appl."},{"key":"10.1016\/j.mcpro.2024.100721_bib142","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00401-017-1691-0","article-title":"Proteomic differences in amyloid plaques in rapidly progressive and sporadic Alzheimer\u2019s disease","volume":"133","author":"Drummond","year":"2017","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.mcpro.2024.100721_bib143","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1002\/alz.13042","article-title":"SCRN1: a cerebrospinal fluid biomarker correlating with tau in Alzheimer's disease","volume":"19","author":"Weiner","year":"2023","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.mcpro.2024.100721_bib144","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jchromb.2013.05.003","article-title":"Targeted human cerebrospinal fluid proteomics for the validation of multiple Alzheimer's disease biomarker candidates","volume":"930","author":"Choi","year":"2013","journal-title":"J.\u00a0Chromatogr. B"},{"key":"10.1016\/j.mcpro.2024.100721_bib145","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1750-1326-9-22","article-title":"Identification of longitudinally dynamic biomarkers in Alzheimer\u2019s disease cerebrospinal fluid by targeted proteomics","volume":"9","author":"Wildsmith","year":"2014","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.mcpro.2024.100721_bib146","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13024-015-0059-y","article-title":"Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay","volume":"10","author":"Heywood","year":"2015","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.mcpro.2024.100721_bib147","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.194","article-title":"A\u00a0targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer\u2019s disease pathology","volume":"6","author":"Paterson","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.mcpro.2024.100721_bib148","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/prca.201400178","article-title":"Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF","volume":"9","author":"Spellman","year":"2015","journal-title":"Proteomics Clin. Appl."},{"key":"10.1016\/j.mcpro.2024.100721_bib149","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13195-017-0335-x","article-title":"Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer\u2019s disease","volume":"10","author":"Duits","year":"2018","journal-title":"Alzheimers Res. Ther."}],"container-title":["Molecular & Cellular Proteomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535947624000112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535947624000112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:25:43Z","timestamp":1778617543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535947624000112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":149,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S1535947624000112"],"URL":"https:\/\/doi.org\/10.1016\/j.mcpro.2024.100721","relation":{},"ISSN":["1535-9476"],"issn-type":[{"value":"1535-9476","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alzheimer's Disease Biomarker Analysis Using Targeted Mass Spectrometry","name":"articletitle","label":"Article Title"},{"value":"Molecular & Cellular Proteomics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcpro.2024.100721","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"100721"}}